Chemistry:Frunevetmab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Rat |
| Target | Nerve growth factor (NGF) |
| Clinical data | |
| Trade names | Solensia |
| License data |
|
| Routes of administration | Subcutaneous |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Frunevetmab, sold under the brand name Solensia, is a medication used to treat pain associated with osteoarthritis in cats.[2]
It is the first monoclonal antibody new animal drug approved by the U.S. Food and Drug Administration (FDA) for use in any animal species.[2]
Frunevetmab is the international nonproprietary name (INN).[4]
Clinical usage
Frunevetmab is a cat-specific monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor (NGF) that is involved in the regulation of pain.[2] When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain.[2]
Frunevetmab is indicated for the alleviation of pain associated with osteoarthritis in cats.[2][3]
The most common side effects seen in cats include vomiting, diarrhea, injection site pain, scabbing on the head and neck, dermatitis, and pruritus (itchy skin).[2]
History
In February 2021, Frunevetmab was approved for medical use in the European Union.[3]
In January 2022, the following year, Frunevetmab was approved for medical use in the United States.[2][5]
Development as a potential drug for humans was stopped due to risk concerns over worsening osteoarthritis. [6]
See also
References
- ↑ "NADA 141-546 Solensia™ frunevetmab injection Injectable Solution Cats". animaldrugsatfda.fda.gov. Archived from the original on 15 January 2022. https://web.archive.org/web/20220115030222/https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11817. [bare URL PDF]
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 "FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species". U.S. Food and Drug Administration (FDA) (Press release). 2022-01-13. Archived from the original on 2022-01-13. Retrieved 2022-01-14.
This article incorporates text from this source, which is in the public domain.
- ↑ 3.0 3.1 3.2 "Solensia EPAR". 11 December 2020. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/solensia. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information 31 (3). 2017.
- ↑ "Zoetis Announces FDA Approval of Solensia (frunevetmab injection) to Control Osteoarthritis Pain in Cats". Zoetis. 2022-01-13. https://news.zoetis.com/press-releases/press-release-details/2022/Zoetis-Announces-FDA-Approval-of-Solensia-frunevetmab-injection-to-Control-Osteoarthritis-Pain-in-Cats/default.aspx.
- ↑ "FDA Approves Pain Reliever for Cats Considered Too Risky for Humans". 14 January 2022. https://www.painnewsnetwork.org/stories/2022/1/14/fda-approves-pain-reliever-for-cats-considered-too-risky-for-humans.
This article incorporates public domain material from the United States Department of Health and Human Services website https://www.fda.gov/.
Bibliography
- "Efficacy and Safety of an Anti-nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study". Frontiers in Veterinary Science 8: 610028. 2021. doi:10.3389/fvets.2021.610028. PMID 34124212.
External links
- "Frunevetmab". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/frunevetmab.
 |  |
